Analysis of optimal dose of thoracic radiotherapy for patients with extensive stage small cell lung cancer
Kunpeng Xu,Li Ming Xu,Jing Luo,Xin Wang,Jian Sun,Wencheng Zhang,Lujun Zhao,Ping Wang
Department of Radiation Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research center for Cancer;Key Laboratory of Cancer Prevention and Therapy,Tian Jin;Tianjin′s Clinical Research Center for Cancer, Tianjin 300060,China
Abstract：Objective To investigate the optimal dosage of thoracic radiotherapy in patients diagnosed with extensive stage small cell lung cancer (ES-SCLC). Methods Clinical data of ES-SCLC patients admitted to Tianjian Medical University Cancer Institute& Hospital between February 2010 and October 2015 were retrospectively analyzed. All patients received the first-line induction chemotherapy. Subsequently, 216 patients without progression after the first-line induction chemotherapy were apportioned to the thoracic radiotherapy (n=180) group and chemotherapy alone group (n=36).According to the distribution characteristics of the biological equivalent dose, all patients were assigned into the A (31.3-40.2 Gy, n=23), B (46.0-46.8 Gy, n=38), C (49.5-53.7 Gy, n=43) and D groups (55.1-60.6 Gy, n=76).For the subgroup analysis, the low (31.3-46.8 Gy, n=61) and high dose groups (49.5-60.6 Gy, n=119) were divided. Kaplan-Meier survival analysis was used for prognostic analysis. Cox’s regression model was conducted for multivariate prognostic analysis. Propensity score matching was utilized to control the confounding variables. Results The median overall survival of all patients was 13.2 months, and 8.3, 11.0, 15.8, 17.8 and 8.1 months for patients in the A, B, C, D and chemotherapy alone groups, respectively (all P=0.000).The median overall survival did not significantly differ between A and B/chemotherapy groups (P=0.172, P=0.495), and similar results were obtained between the C and D groups (P=0.624).The median overall survival in the B group was significantly longer than that in the chemotherapy alone group (P=0.020).Statistical significance was noted between C and D groups, and A and B groups (all P<0.05).The median progression-free survival for all patients was 8.7 months, and 6.5, 7.6, 11.8, 12.4 and 6.1 months in the A, B, C, D and chemotherapy alone groups, respectively (all P=0.000).The median progression-free survival did not significantly differ between A and B chemotherapy groups (P=0.588, P=0.668).The progression-free survival in the B group was slightly longer than that in the chemotherapy group without statistical significance (P=0.070).No statistical significance was observed between the C and D groups (P=0.627).Statistical significance was noted between C and D groups, and A and B groups (all P<0.02).Uni-and multi-variate analyses prompted that the number of metastatic lesions and dose of thoracic radiotherapy were the independent predictors of the overall survival and progression-free survival (both P<0.05).Concurrent chemoradiotherapy was the independent predictor of the overall survival (P=0.018).After the propensity score matching, the median overall survival and progression-free survival significantly differed between the low (n=50) and high dose groups (n=50)(10.9 vs. 17.5 months, P=0.045;7.4 vs. 10.7 months, P=0.014). Conclusions A relatively high dose ranging from 49.5 to 53.7 Gy is recommended during thoracic radiotherapy for ES-SCLC patients. An excessively low dose (≤40.2 Gy) probably fails to prolong the survival time, and an extremely high dose (≥55.1 Gy) cannot enable the patients to obtain survival benefits.
Kunpeng Xu,Li Ming Xu,Jing Luo et al. Analysis of optimal dose of thoracic radiotherapy for patients with extensive stage small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2019, 28(3): 180-184.
[1] Govindan R,Page N,Morgensztern D,et al. Changing epidemiology of small-cell lung cancer in the United States Ooer the last 30 years:analysis of the surveillance,epidemiologic,and end results database[J].J Clin Oncol,2006,24(28):4539-4544-.DOI:10.1200/JCO.2005.04.4859. [2] Parikh M,Riess J,Jr PNL,et al. New and emerging developments in extensive stage small celllung cancer therapeutics[J].Curr Opin Oncol,2016,28(2):97-97.DOI:10.1097/CCO.0000000000000264. [3] Tartarone A,Giordano P,Lerose R,et al. Progress and challenges in the treatment of small cell lung cancer[J].Med Oncol,2017,34(6):110-110.DOI:10.1007/s12032-017-0966-6. [4] Evans WK,Shepherd FA,Feld R,et al. VP-16 and cisplatin as first-line therapy for small-cell lung cancer[J].J Clin Oncol,1985,3(11):1471-7.DOI:10.1200/JCO.1985.3.11.1471. [5] Jeremic B,Shibamoto Y,Nikolic N,et al. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer:a randomized study[J].J Clin Oncol,1999,17(7):2092-9.DOI:10.1200/JCO.1999.17.7.2092. [6] Slotman BJ,van Tinteren H,Praag JO,et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer:a phase 3 randomised controlled trial[J].TheLancet,2017,385(9962):36-42.DOI:10.1016/S0140-6736(14)61085-0. [7] Mahmoud O,Kwon D,Greenfield B,et al. Intrathoracic extensive-stage small cell lung cancer:assessment of the benefit of thoracic and brain radiotherapy using the SEER database[J].Int J Clin Oncol,2016,87(2):1-9-.DOI:10.1007/s10147-016-1011-z. [8] Gore EM,Hu C,Sun AY,et al. Randomized Phase Ⅱ Study Comparing Prophylactic Cranial Irradiation Alone To Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC):NRG Oncology RTOG 0937[J].J Clin Oncol,2017,12(10):1561-1561.DOI:10.1016/j.jtho.2017.06.015. [9] Socinski M A, Smit E F, Lorigan P, et al. Phase Ⅲ Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer[J]. Journal of Clinical Oncology, 2009, 27(28):4787-4792.DOI:10.1200/JCO.2009.23.1548. [10] Zhu H,Zhou Z,Wang Y,et al. Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis[J].Cancer,2011,117(23):5423-31.DOI:10.1002/cncr.26206. [11] Lara PN Jr,Natale R,Crowley J,et al. Phase Ⅲ trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer:clinical and pharmacogenomic results from SWOG S0124[J].J Clin Oncol,2009,27(15):2530-5.10.1200/JCO.2008.20.1061. [12] Nōu E,Brodin O,Bergh J.A randomized study of radiation treatment in small cell bronchial carcinoma treated with two types of four-drug chemotherapy regimens[J].Cancer,1988,62(6):1079-1090. [13] Livingston RB,Moore TN,Heilbrun L,et al. Small-cell carcinoma of the lung:combined chemotherapy and radiation:a Southwest Oncology Group study[J].Ann Intern Med,1978,88(2):194-194. [14] Diniz G,Unlu I,Gokce T,et al. Evaluation of curative and palliative radiotherapy efficacy in extensive stage small cell lung cancer[J].Saudi Med J,2006,27(7):992-996. [15] Luan Z,Wang Z,Huang W,et al. Efficacy of 3D conformal thoracic radiotherapy for extensive-stage small-cell lung cancer:a retrospective study[J].Exp Thera Med,2015,10(2):671-671.DOI:10.3892/etm.2015.2526. [16] Slotman BJ,Faivre-Finn C,Van TH,et al. Which patients with ES-SCLC are most likely to benefit from more aggressive radiotherapy:a secondary analysis of the Phase Ⅲ CREST trial[J].Lung Cancer,2017,108:150-150.DOI:10.1016/j.lungcan.2017.03.007. [17] 罗婧,徐利明,赵路军等.不同放化疗组合方案对广泛期SCLC预后影响[J].中华放射肿瘤学杂志,2016,25(11):1166-1171.DOI:10.3760/cma.j.issn.1004-4221.2016.11.005. Luo J,Xu LM,Zhao LJ,et al. Effects of different chemoradiotherapy schemes on the prognosis of extensive-stage small-cell lung cancer[J].Chin J Radiat Oncol,2016,25(11):1166-1171.DOI:10.3760/cma.j.issn.1004-4221.2016.11.005. [18] 罗婧,徐利明,赵路军,等.322例广泛期SCLC不同转移部位的生存分析[J].中华放射肿瘤学杂志,2017,26(1):17-21.DOI:10.3760/cma.j.issn.1004-4221.2017.01.004. Luo J,Xu LM,Zhao LJ,et al. The survival analysis of different metastasis sites for 332 patients of extensive stage small cell lung cancer[J].Chin J Radiat Oncol,2017,26(1):17-21.DOI:10.3760/cma.j.issn.1004-4221.2017.01.004. [19] 徐利明,赵路军,陈秀丽等.广泛期SCLC不同放疗分割方式疗效比较[J].中华放射肿瘤学杂志,2015,(5):488-492.DOI:10.3760/cma.j.issn.1004-4221.2015.05.003. Xu LM,Zhao LJ,Chen XL,et al. Comparison of efficacy of different fractionation schedules in radiotherapy for extensive-stage small cell lung cancer[J].Chin J Radiat Oncol,2015,(5):488-492.DOI:10.3760/cma.j.issn.1004-4221.2015.05.003.
2019, Vol. 28 
